

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 00719)

UNAUDITED FIRST QUARTER RESULTS OF 2023

(for the period commencing from 1 January 2023 to 31 March 2023)

This announcement is made pursuant to rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”) hereby announces the unaudited consolidated results of the Company and its subsidiaries (the “**Group**”) for the 3 months ended 31 March 2023. The financial information set out in this announcement has been prepared in accordance with the CASBE (as defined under the Listing Rules) and has been reviewed and approved by the Audit Committee of the Board.

The Board and the supervisory committee of the Company and its directors, supervisors and senior management, and persons in charge of the accounting function warrant that there are no false presentations or misleading statements contained in, or material omissions from, this announcement, and severally and jointly accept legal responsibility for the authenticity, accuracy and completeness of the information contained in this announcement.

This announcement is simultaneously available on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk and the website of the Company at <http://www.xhzy.com>. The first quarterly report of 2023 prepared in accordance with the CASBE will also be available at <http://www.cninfo.com.cn>.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

This announcement was prepared in both Chinese and English. In the event of any inconsistencies between the two versions, the Chinese version shall prevail.

I. KEY ACCOUNTING AND FINANCIAL DATA

Item	Jan - Mar 2023 (Unaudited) RMB Yuan	Jan - Mar 2022 (Unaudited) RMB Yuan	Change as compared to the same period of last year
Operating income	2,639,665,769.78	1,831,254,151.22	44.15%
Net profit attributable to shareholders of listed company	151,603,818.36	108,503,552.76	39.72%
Net profit attributable to shareholders of listed company after deduction of non-recurring profit and loss	147,158,093.14	105,056,286.76	40.08%
Net cash flow from operating activities	(183,742,803.27)	(17,713,946.61)	(937.28%)
Basic earnings per share (RMB Yuan / Share)	0.23	0.17	35.29%
Diluted earnings per share (RMB Yuan / Share)	0.22	0.17	29.41%
Ratio of weighted average return on net assets (%)	3.59%	3.07%	Increased by 0.52 percentage points
Item	As at 31 Mar 2023 (Unaudited) RMB Yuan	As at 31 Dec 2022 (Audited) RMB Yuan	Change as compared to the end of last year
Total assets	7,976,649,915.84	8,265,131,332.13	(3.49%)
Net assets attributable to the shareholders of listed company	4,323,961,931.78	4,126,460,390.95	4.79%

II. PROFIT AND LOSS ACCOUNT

Item	Jan - Mar 2023		Jan - Mar 2022	
	Consolidated (Unaudited) RMB Yuan	Parent company (Unaudited) RMB Yuan	Consolidated (Unaudited) RMB Yuan	Parent company (Unaudited) RMB Yuan
I. Gross revenue	2,639,665,769.78	1397782678.67	1,831,254,151.22	1,002,004,272.71
Including: Operating revenue	2,639,665,769.78	1397782678.67	1,831,254,151.22	1,002,004,272.71
II. Total operating costs	2,460,141,970.67	1,158,916,760.22	1,703,734,749.93	911,825,557.07
Including: Operating costs	1,811,323,065.52	936,802,233.21	1,330,503,580.57	748,758,576.56
Taxes and surcharges	42,055,615.47	15,002,808.42	16,364,788.47	9,207,565.21
Selling expenses	352,901,998.18	12,912,682.48	164,351,093.20	4,450,126.47
Administration expenses	126,174,409.90	89,394,185.45	101,487,496.49	75,514,004.40
R&D costs	112,119,587.26	89,429,421.07	78,758,186.08	61,051,761.54
Financial expenses	15,567,294.34	15,375,429.59	12,269,605.12	12,843,522.89
Including: Interest expense	11,804,437.54	11,333,803.04	12,534,163.31	12,585,247.24
Interest income	3,701,993.16	3,231,135.42	1,413,742.17	768,709.94
Add: Other income	5,670,706.38	5,235,892.41	5,585,738.92	5,356,679.17
Investment income (losses to be listed with brackets)	78,030.02	78,030.02	146,951.83	146,951.83

Including: Return on investment on joint ventures and joint ventures (losses to be listed with brackets)	78,030.02	78,030.02	146,951.83	146,951.83
Credit impairment loss (losses to be listed with brackets)	500.00	-	-	-
Assets impairment loss (losses to be listed with brackets)	-	-	-	-
Gains from asset disposal (losses to be listed with brackets)	525,019.96	520,089.31	457,968.33	425,117.83
III. Operating profits (losses to be listed with brackets)	185,798,055.47	244,699,930.19	133,710,060.37	96,107,464.47
Add: non-operating income	359,782.90	200,938.36	209,616.77	83,354.54
Less: non-operating expenditure	1,238,527.22	1,017,560.32	1,976,163.07	648,087.50
IV. Total profits (total loss to be listed with brackets)	184,919,311.15	243,883,308.23	131,943,514.07	95,542,731.51
Less: income tax expense	30,908,896.72	36,570,791.73	22,524,965.64	14,309,366.95
V. Net profits (net loss to be listed with brackets)	154,010,414.43	207,312,516.50	109,418,548.43	81,233,364.56
(I) According to operation continuity				
1. Net profit from continued operations (net losses to be listed in brackets)	154,010,414.43	207,312,516.50	109,418,548.43	81,233,364.56
2. Net profit from discontinued operations (net losses to be listed in brackets)	-	-	-	-
(II) According to ownership				
1. Net profit attributable to shareholders of parent company	151,603,818.36	-	108,503,552.76	-
2. Minority interest income or loss	2,406,596.07	-	914,995.67	-
VI. Net amount of other comprehensive income after tax	7,709,824.55	8,534,938.40	(14,598,551.00)	(14,356,840.00)
Net amount of other comprehensive income after tax attributable to the shareholders of parent company	7,890,797.98	-	(14,545,379.17)	-
(I) Other comprehensive income not subject to reclassification to profit or loss	8,534,938.40	8,534,938.40	(14,356,840.00)	(14,356,840.00)
Changes in fair value of other equity instruments investment	8,534,938.40	8,534,938.40	(14,356,840.00)	(14,356,840.00)
(II) Other comprehensive income to be reclassified to profit or loss	(644,140.42)	-	(188,539.17)	-

Conversion difference of foreign currency statement	(644,140.42)	-	(188,539.17)	-
Net amount of other comprehensive income after tax attributable to the minority shareholders	(180,973.43)	-	(53,171.83)	-
VII. Total comprehensive income	161,720,238.98	215,847,454.90	94,819,997.43	66,876,524.56
Total comprehensive income attributable to the shareholders of parent company	159,494,616.34	-	93,958,173.59	-
Total comprehensive income attributable to the minority shareholders	2,225,622.64	-	861,823.84	-
VIII. Earnings per share:				
(I) Basic earnings per share	0.23	-	0.17	-
(II) Diluted earnings per share	0.22	-	0.17	-

III. Changes in Accounting Policies

Contents and reasons of accounting policy changes	Approval processes	Notes
<p>The Ministry of Finance issued the interpretation of accounting standards for Business Enterprises No. 16 (Finance and Accounting [2022] No. 31) (hereinafter referred to as "Interpretation No. 16") on 30 November 2022.</p> <p>Interpretation No. 16 clarifies "Accounting treatment regarding the non-application of initial recognition exemption to deferred income tax related to assets and liabilities arising from individual transactions" (effective January 1, 2023), "Accounting Treatment regarding the income tax impact of dividends related to financial instruments classified by the Issuer as equity instruments" (effective as of the date of publication), and "Accounting Treatment regarding the fact that the Enterprise will be settled in cash Accounting Treatment of Stock Payments settled with equity (effective as of the date of publication). In accordance with the requirements of Interpretation No. 16, the Company changes its current accounting policies accordingly.</p>	<p>Relevant accounting policy changes were approved at the 11th meeting of the 10th Board of the Company on 20 April 2023.</p>	<p>Changes in relevant accounting policies have no significant impact on the Group's financial statements.</p>

By Order of the Board
Shandong Xinhua Pharmaceutical Company Limited
He Tongqing
Chairman

20 April 2023, Zibo, PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. He Tongqing (Chairman)

Mr. Xu Wenhui

Mr. Hou Ning

Non-executive Directors:

Mr. Xu Lie

Mr. Cong Kechun

Independent Non-executive Directors:

Mr. Pan Guangcheng

Mr. Zhu Jianwei

Mr. Lo Wah Wai

Mr. Ling Peixue